The prospective screening for SARS-CoV-2 S1/S2 antibodies delineates the factual incidence of COVID-19 and shows a sustained serological response <i>post</i> COVID-19 in kidney transplant recipients
General Medicine; Transplantation; COVID19; Serology; Epidemiology; Nephrology
Abstract :
[en] The impact of immunosuppression on the occurrence of Coronavirus Disease 2019 (COVID-19) remains unclear. We conducted a prospective screening of anti-S1/S2 IgGs against SARS-CoV-2 Spike protein from March, 1 2020 to May, 15 2021 (prior to the vaccination campaign) in a cohort of 713 kidney transplant recipients (KTRs). In a first phase, the factual incidence and seroprevalence of COVID-19 was established in this cohort: cases diagnosed by serology were added to RT-PCR-based diagnoses to obtain the overall incidence of COVID-19 in both symptomatic and asymptomatic KTRs. In the second phase, the kinetics of the post-COVID-19 humoral response were studied, taking into account the severity of the disease defined by the need for oxygen therapy (group S, "severe") or not (group nS, "not severe"). The combined diagnostic approaches identified 138 COVID-19 cases (19.2%), with 37 diagnoses by serology (26.8%). The rate of asymptomatic KTRs reached 20.3% (28/138). Thirteen patients (9.4%) died from COVID-19. The seroconversion rate was 91.7% (99/108). The peak anti-S1/S2 IgG level was 85 [30-150] AU/ml and was similar between the S and nS groups (117 [38; 186] AU/ml versus 73 [23; 140] AU/ml). A high probability of persistence of anti-S1/S2 IgG post-COVID-19 was observed, with only 10.1% (7/69) of the patients having negated their serology during the 9-month follow-up. In conclusion, our pragmatic serological screening combined with RT-PCR tests provides a better estimation of the real incidence of COVID-19 in KTRs. A significant proportion of KTRs develop humoral immunity post COVID-19, which most often persists beyond 9 months.
Disciplines :
Immunology & infectious disease
Author, co-author :
Firket, Louis ; Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie
Bouquegneau, Antoine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie
Seidel, Laurence ; Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME)
BONVOISIN, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie
GROSCH, Stéphanie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie
Hayette, Marie-Pierre ; Centre Hospitalier Universitaire de Liège - CHU > > Service de microbiologie clinique
Jouret, François ; Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie
WEEKERS, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie
Language :
English
Title :
The prospective screening for SARS-CoV-2 S1/S2 antibodies delineates the factual incidence of COVID-19 and shows a sustained serological response <i>post</i> COVID-19 in kidney transplant recipients
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506.
Bouquegneau A, Erpicum P, Grosch S, et al. COVID-19–associated nephropathy includes tubular necrosis and capillary congestion, with evidence of SARS-CoV-2 in the nephron. Kidney360. 2021; 2: 639–652.
Huart J, Bouquegneau A, Lutteri L, et al. Proteinuria in COVID-19: prevalence, characterization and prognostic role. J Nephrol. 2021; 34: 355–364.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395: 1033–1034.
Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med. 2007; 28: 222–242.
Firket L, Descy J, Seidel L, et al. Serological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2. Am J Transplant. 2021; 21: 3806–3807.
Turbett SE, Anahtar M, Dighe AS, et al. Evaluation of three commercial SARS-CoV-2 Serologic assays and their performance in two-test algorithms. J Clin Microbiol. 2020; 59. DOI: 10.1128/JCM.01892-20.
Ma Q, Liu J, Liu Q, et al. global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. JAMA Network Open. 2021; 4: e2137257–e2137257.
Pinchera B, Spirito L, Ferreri L, et al. SARS-CoV-2 in kidney transplant patients: a real-life experience. Front Med. 2022; 9: 864865.
Alberici F, Delbarba E, Manenti C, et al. A report from the brescia renal COVID task force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. Kidney Int. 2020; 98: 20.
Benotmane I, Perrin P, Vargas GG, et al. Biomarkers of cytokine release syndrome predict disease severity and mortality from COVID-19 in kidney transplant recipients. Transplantation 2021. 105(1): 158–169.
Bossini N, Alberici F, Delbarba E, et al. Kidney transplant patients with SARS-CoV-2 infection: the brescia renal COVID task force experience. Am J Transplant. 2020; 20: 3019–3029.
Caillard S, Anglicheau D, Matignon M, et al. An initial report from the French SOT COVID registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney Int. 2020; 98: 1549–1558.
Crespo M, Mazuecos A, Rodrigo E, et al. Respiratory and gastrointestinal COVID-19 phenotypes in kidney transplant recipients. Transplantation 2020. 104(11): 2225–2233.
Demir E, Uyar M, Parmaksiz E, et al. COVID‐19 in kidney transplant recipients: a multicenter experience in Istanbul. Transpl Infect Dis. 2020; 22. 10.1111/TID.13371.
Elias M, Pievani D, Randoux C, et al. COVID-19 infection in kidney transplant recipients: disease incidence and clinical outcomes. J Am Soc Nephrol. 2020; 31: 2413–2423.
Favà A, Cucchiari D, Montero N, et al. Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: a multicentric cohort study. Am J Transplant. 2020; 20: 3030–3041.
Sánchez-Álvarez JE, Fontán MP, Martín CJ, et al. Situación de la infección por SARS-CoV-2 en pacientes en tratamiento renal sustitutivo. Informe del Registro COVID-19 de la Sociedad Española de Nefrología (SEN). Nefrologia. 2020; 40: 272.
Hadi YB, Naqvi SFZ, Kupec JT, et al. Outcomes of COVID-19 in solid organ transplant recipients: a propensity-matched analysis of a large research network. Transplantation. 2021; 105: 1365–1371.
Becchetti C, Broekhoven AGC, Dahlqvist G, et al. Humoral response to SARS-CoV-2 infection among liver transplant recipients. Gut. 2022; 71: 746–756.
Burack D, Pereira MR, Tsapepas DS, et al. Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant recipients with confirmed infection. Am J Transplant. 2021; 21: 2254–2261.
Chang CC, Vlad G, Vasilescu ER, et al. Disparity between levels of anti-RBD IgG and anti-nucleocapsid protein IgG antibodies in COVID-19–recovered patients who received a kidney transplant. Kidney Int. 2021; 100: 240.
Chavarot N, Leruez-Ville M, Scemla A, et al. Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection. Kidney Int. 2021; 99: 486–488.
Prendecki M, Clarke C, Gleeson S, et al. Detection of SARS-CoV-2 antibodies in kidney transplant recipients. J Am Soc Nephrol. 2020; 31: 2753–2756.
Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27: 1205–1211. 277.
Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020; 396: 1595–1606.
Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology. 2020; 5: 1598–1607.
Benotmane I, Gautier Vargas G, Velay A, et al. Persistence of SARS-CoV-2 antibodies in kidney transplant recipients. Am J Transplant. 2021a; 21: 2307–2310.
Søfteland JM, Gisslén M, Liljeqvist JA, et al. Longevity of anti-spike and anti-nucleocapsid antibodies after COVID-19 in solid organ transplant recipients compared to immunocompetent controls. Am J Transplant. 2022; 22: 1245–1252.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.